XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...
Kalkine Media

Royalty Pharma plc (NASDAQ:RPRX) Nasdaq Index Life Sciences Partner

Royalty Pharma plc operates a diversified royalty portfolio while appearing in broader discussions tied to the nasdaq 100 ...
TipRanks on MSN

Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement

XOMA Royalty (XOMA) has amended its collaboration, originally established in 2006, with Takeda (TAK) through a strategic royalty share ...
The Caledonian-Record

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing ...

Oak Hill Bio and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of bronchopulmonary dysplasia in premature infants. Additional Oak Hill Bio assets that have ...
The Pharma Letter

XOMA and Takeda execute royalty sharing transaction

US biotech royalty aggregator XOMA Royalty Corp announced it has amended its collaboration, originally established in 2006, ...